Dermatology

Login Register

This site is intended for healthcare professionals only

Login Register

MD Brand Connect
Vaccine Hub
MDTV
Fact Check
Health Dialogues

Medical News & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry
MDTV

This site is intended for healthcare professionals only

Login Register

LoginRegister

Home
Medical news & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry

Home

emcure pharma

Tag: emcure pharma

Read all Latest developments, information and news on and about emcure pharma - Page 3

Emcure Pharma is an Indian pharmaceutical company headquartered in Pune, Maharashtra. Emcure's product portfolio includes tablets, capsules, and injectables.

Emcure Pharma Expands Its Dermatology Portfolio

Emcure Pharmaceuticals Gets CDSCO To Manufacture & Market the FDC Antiviral Drug

Dr. Divya Colin4 May 2023 6:00 PM IST

New Delhi: Granting approval for bioequivalence (BE) study and clinical trial (CT) study waiver, the Subject Expert Committee (SEC) functional under...

Emcure Pharma wins Merit Award at HIV Congress 2023

Ruchika Sharma9 April 2023 10:00 AM IST

Pune: Emcure Pharmaceuticals, a Indian pharmaceutical company, has been felicitated for its contributions to HIV/AIDS research and development at the...

Patient dies from suspected drug reaction to Emcure Pharma Orofer FCM, Maha FDA issues nationwide recall

Roshni Dhar25 Nov 2022 5:37 PM IST

Drug maker Emcure Pharmaceuticals Ltd. has landed in trouble after a patient at Saifee Hospital administered iron supplement, Orofer FCM (ferric...

Health Bulletin 25/November/2022

Roshni Dhar25 Nov 2022 4:51 PM IST

Here are the top health news for the day:Thirteen measles deaths reported in Mumbai An eight-year-old boy from Govandi died on Thursday due to...

Patient dies from suspected drug reaction to Emcure Pharma's Orofer FCM, Maha FDA issues nationwide recall

Farhat Nasim24 Nov 2022 5:48 PM IST

Pune: Drug maker Emcure Pharmaceuticals Ltd. has landed in trouble after a patient at Saifee Hospital administered iron supplement, Orofer FCM (ferric...

HC restrains pharma companies from infringing Boehringer Ingelheim diabetes drug Linagliptin

Susmita Roy8 Jun 2022 4:04 PM IST

New Delhi: In a major relief to pharmaceuticals major Boehringer Ingelheim, the High Court has restrained four domestic pharma companies namely,...

NPPA fixes price of 84 formulations, revises 1

Ruchika Sharma13 May 2022 3:00 PM IST

New Delhi: Through a recent notice, the National Pharmaceutical Pricing Authority (NPPA) has fixed the retail prices of 84 formulations and has...

Ahead of Linagliptin going off-patent, NPPA fixes retail price of its FDC with Metformin

Susmita Roy20 April 2022 6:57 PM IST

New Delhi: With the popular antidiabetic drug Linagliptin soon expected to go off-patent, the apex drug price regulator, National Pharmaceutical...

NPPA fixes retail prices of 15 formulations, ceiling price of Framycetin

Ruchika Sharma19 April 2022 4:06 PM IST

New Delhi: National Pharmaceutical Pricing Authority (NPPA), Ministry of Chemicals and Fertilizers, Government of India has fixed retail prices of 15...

Bain Capital backed Emcure Pharma files draft IPO papers with SEBI

Ruchika Sharma20 Aug 2021 1:09 PM IST

New Delhi: Bain Capital-backed Emcure Pharmaceuticals has filed preliminary papers with capital markets regulator Sebi to raise funds through an...

Setback to Emcure: NPPA refers back price fixation issue of Darunavir, Ritonavir FDC to DoP

Medical Dialogues Team9 Aug 2021 2:14 PM IST

New Delhi: Holding that data is not available, the National Pharmaceuticals Pricing Authority (NPPA) has referred the matter of fixing the retail...

Emcure Pharma eyes to be among top 5 drug firms: Official

Ruchika Sharma9 Aug 2021 1:00 PM IST

New Delhi: Emcure Pharmaceuticals is aiming to be among the top five drug firms in the country in the next five to seven years as it also eyes...

Powered By: Hocalwire

X

We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok